Introduction
Interstitial lung disease (ILD) is a heterogeneous group of noninfectious, nonmalignant disorders of the lower respiratory tract, characterized by infiltration of inflammatory cells and interstitial fibrosis. Since the original description of ILD in a case of dermatomyositis by Mills and Mathews [1] in 1956, the association of ILD with polymyositis/dermatomyositis has been widely accepted. In another subset of inflammatory myopathies, inclusion body myositis, ILD seems to be infrequent; we found only a few reports of ILD in this subset [2] . The presence of ILD in patients with myositis affects the prognosis and contributes substantially to morbidity and mortality [3] [4] [5] . Although this review focuses on current concepts regarding ILD associated with polymyositis/dermatomyositis, it should be emphasized that not only the myositis itself but also the immunosuppressive treatment and secondary infections caused by immunosuppressive therapy used in these patients might lead to development of interstitial pneumonia and cause diagnostic and therapeutic dilemmas.
Incidence
The reported incidence of ILD in polymyositis/dermatomyositis varies between 5% and 46% in earlier crosssectional studies, depending on whether clinical, radiologic, functional, or pathologic criteria have been used [4] [5] [6] [7] [8] . In a recent prospective study of 17 patients with newly diagnosed polymyositis/dermatomyositis, 11 patients (65%) were diagnosed with ILD at onset of diagnosis [9 •• ] . In this study, ILD was defined as the occurrence of radiographic signs of ILD on chest radiograph and/or high-resolution computerized tomography (HRCT) and/or restrictive ventilatory defect with reduced lung volumes. This frequency was higher than that reported in previous studies despite its restriction to newly diagnosed cases and excluding patients with cancer and overlap syndromes. The high incidence of ILD in this study could be a result of the systematic use of sensitive detection methods such as HRCT and pulmonary function tests. Moreover, all new patients with myositis were investigated regardless of clinical lung symptoms, and some asymptomatic patients were detected with signs of ILD using these tests. It is likely that the reported incidence of ILD will increase even further with the increasing use of other sensitive diagnostic methods such as bronchoalveolar lavage (BAL), as has been reported in patients with other connective tissue diseases [10, 11] . Adult patients with polymyositis and dermatomyositis seem to be equally predisposed to develop ILD. Data on prevalence of ILD in juvenile dermatomyositis are limited. According to one study, about half of the patients in a small case series of 12 patients with juvenile dermatomyositis had asymptomatic lung disease detected by pulmonary function tests [12] .
Clinical features of interstitial lung disease
The clinical manifestations of ILD in patients with polymyositis or dermatomyositis may vary from asymptomatic to severe, rapidly progressive dyspnea with pulmonary insufficiency and fatal outcome. Patients with polymyositis and dermatomyositis with ILD have been described with three different clinical patterns of the ILD based on the clinical symptoms: those with an acute onset of symptoms, those who present with chronic, slowly progressive symptoms, and those without pulmonary symptoms but abnormal chest radiographs or pulmonary function tests [13] . Cough and dyspnea are the most commonly reported symptoms, although ILD is also reported to occur in patients without any clinical overt signs of pulmonary involvement. In one study, 27% of the patients with myositis with ILD were asymptomatic; inversely, two-thirds of the patients without any signs of ILD on radiograph/HRCT or reduction of lung volumes had either cough or dyspnea [ 
Other clinical or laboratory signs should also raise the awareness of a concomitant ILD in patients with polymyositis or dermatomyositis. The strongest predictive factor for ILD in patients with myositis is the presence of positive anti-aminoacyl tRNA synthetase antibodies, of which the anti-histidyl tRNA synthetase antibody (anti-Jo1) is the most frequently found, in approximately 20% of patients with myositis. The reported frequency of ILD in patients with anti-Jo1 antibodies is more than 70% [3,9 •• , 14, 15] . Clinical manifestations other then skin and muscle involvement that occur frequently in patients with ILD and myositis are arthralgia/arthritis, fever, Raynaud's phenomenon, and mechanics hands, known as manifestations of the antisynthetase syndrome [14, 15] . In addition to positive antiJo1 antibodies, elevated levels of Krebs von den lungen-6 (KL-6), a glycoprotein expressed on type II alveolar pneumocytes and bronchiolar epithelial cells, and serum surfactant protein D are suggested to be useful as markers for ILD in patients with polymyositis/dermatomyositis [16] [17] [18] .
It has been established that ILD can appear concomitantly with, before, or after the onset of skin or muscle manifestations [3, 6, 19] . Case reports even exist of ILD and polymyositis or dermatomyositis 'sine myositis' at presentation in some patients with an acute-onset, rapidly progressive interstitial lung disease [20 • , 21, 22] . The most frequently reported physical finding is bibasilar crepitate rales.
Diagnosis of interstitial lung disease
Clinical respiratory symptoms are not reliable signs to detect ILD in patients with myositis, because neither cough nor dyspnea may be present as early signs. The most useful tests to diagnose ILD are pulmonary function tests, which typically show a restrictive ventilatory defect with decreased total lung capacity, functional residual capacity, residual volume, forced expiatory volume in 1 second (FEV 1 ), and forced vital capacity (FVC), but with a normal or elevated FEV 1 /FVC ratio and a decreased diffusing capacity for carbon monoxide (DLco) (Fig. 1) . Not all of these abnormalities may be found in every patient, however. The most sensitive test seems to be the DLco, but a decreased DLco is not specific for ILD and can also be seen in pulmonary hypertension, for example. Chest radiographs, including serial examinations, are highly useful as screening tests and for detection of complications of ILD such as pneumothoraces, but are rarely useful in detecting early ILD. A normal chest radiograph has been found in approximately 10% of the patients with biopsy-proven diffuse lung disease [23] . Compared with chest radiograph, HRCTof the lungs has a higher sensitivity to detect ILD (Figs. 2 and 3) . HRCT is now widely used not only for detection of ILD but also for identifying the extent and severity of the disease as well as to discriminate between fibrotic disease and active inflammation in the lungs [24] [25] [26] . The most common findings on HRCT are irregular linear opacities with areas of consolidation and ground glass attenuation, suggesting active inflammation (Fig. 3) . Honeycombing indicative of 'end-stage lung' has not been a common finding in patients with myositis
Lung biopsies are not routinely performed in patients with myositis with signs of ILD for diagnostic purposes because of the potential morbidity associated with surgical lung biopsy [7] . Transbronchial biopsies are rarely helpful in the diagnostic procedures, although they are usually abnormal, because the histopathologic findings are nonspecific. Furthermore, previous studies have shown that the HRCT could predict the histologic appearance of ILD in open lung biopsy specimens [24] [25] [26] 31] . A lung biopsy could be helpful to determine prognosis, however, because different histopathology features predict response to corticosteroid treatment.
Bronchoalveolar lavage is a safe, noninvasive, and generally well tolerated procedure. BAL is useful in identifying other causes of interstitial lung disease such as infections, druginduced pneumonitis, and sarcoidosis. Moreover, the BAL fluid cell profile may have a supportive role in the assessment of disease activity and prognosis and guiding of therapy in patients with myositis-associated ILD [3, 19] .
Anti-Jo1 antibodies could not be used as a diagnostic tool for ILD, but because these auto-antibodies are highly associated with ILD, their presence requires careful evaluation of lung involvement using lung function tests and HRCT.
Pathogenesis and histopathology of interstitial lung disease in myositis
The mechanisms that cause ILD in patients with myositis could be several on the basis of the various histopathologic features that have been observed. Studies describing the histopathology of ILD in polymyositis/dermatomyositis have shown several patterns, including bronchiolitis obliterans with organizing pneumonia (BOOP; or cryptogenic organizing pneumonia), diffuse alveolar damage (DAD), nonspecific interstitial pneumonia (NSIP), and usual interstitial pneumonia (UIP) [3,7,30,32 •• ]. These are not specific for ILD with myositis but are identical to those found in idiopathic pulmonary fibrosis. That the mechanisms could vary is further supported by the varying responsiveness to immunosuppressive therapy, which is correlated with different histopathologic patterns. Thus, BOOP responds favorably to corticosteroids. Histopathology compatible with DAD, UIP, or acute interstitial pneumonia responds poorly to corticosteroids and other immunosuppressive therapies and has a poor prognosis [33] . The histopathologic subgroup NSIP encompasses Chest radiograph of a 65-year-old woman with recent onset of polymyositis demonstrates bilateral diffuse opacities subpleural, particularly at the lung bases (same patient as in Figs. 1 and 3) . a varying degree of alveolar wall inflammation or fibrosis, and the response to corticosteroids depends on the degree of inflammation or fibrosis [7, 34] 
Prognosis and prognostic markers of interstitial lung disease in myositis
Although the prognosis for patients with ILD and myositis varies, ILD is considered to be a major risk factor for premature death in patients with myositis. According to two recently reported studies, 1-year survival of patients with polymyositis and dermatomyositis with ILD was 85.8% in one study and 94.4% in the another, 3-year survival was 74.4% or 90.4%, and 5-year survival was 60.4% or 86.5% [3, 30] . Negative prognostic factors for survival in patients with ILD were Hamman-Rich-like syndrome (acute interstitial pneumonia), initial diffusing capacity of carbon monoxide less than 45%, neutrophil alveolitis, and histo- High-resolution computerized tomography could also be helpful as a prognostic tool, because certain patterns of ILD observed on HRCT correlate well with findings on open lung biopsy [24] [25] [26] 31] . Thus, a reticular pattern on computed tomography (CT) scan of the lungs correlated with a histologic finding of fibrosis, whereas a ground glass pattern correlated with reversible inflammatory disease and a better prognosis in patients with fibrosing alveolitis [35] .
The cellular composition of BAL fluid could have a prognostic value. In idiopathic pulmonary fibrosis, a high number of lymphocytes in BAL fluid represents a favorable outcome, while neutrophils and/or eosinophils in BAL fluid were associated with a poor outcome [36] . Resembling idiopathic pulmonary fibrosis, polymyositis/dermatomyositis-associated ILD with neutrophil alveolitis had a progressive, deteriorating course [3, 19] . In a study by Schnabel et al. [19] , all patients with progressive ILD had an increased number of neutrophils in BAL fluid and also tended to have a higher eosinophil count than nonprogressive patients.
Whether serum markers could have a prognostic value is less clear. Once ILD has developed, the presence of antiJo1 antibodies does not appear to have a prognostic value for outcome of ILD [3,30,37 •• ]. The overall prognosis seems to be worse in patients with anti-Jo1 antibodies, however, compared with patients without these antibodies [15] .
A new interesting serum marker with a potential of carrying prognostic value is KL-6. Elevated serum concentrations of KL-6 correlated not only with presence of ILD but also with severity of disease [16, 17] . In a study of 42 adult patients with polymyositis and dermatomyositis, elevated serum KL-6 levels correlated with presence of ILD and decreased percentage diffusing capacity of carbon monoxide and percentage vital capacity [16] . Bandoh et al. [17] demonstrated that KL-6 concentrations in sera of six patients with polymyositis or dermatomyositis were associated with interstitial pneumonia and changed according to the progression or improvement of interstitial pneumonia. Although this marker needs to be tested in larger patient cohorts over time, and serum levels need to be compared with appropriate outcome measures for lung function, it is interesting as a possible future serum marker for prognostic evaluation.
Serum surfactant protein D was also found to be increased in patients with ILD associated with polymyositis/dermatomyositis. The level of serum surfactant protein D was inversely correlated with vital capacity and DLco in those patients [18] . Whether this marker is sensitive to changes with time and thus could be used as a prognostic marker in patient treatment needs to be investigated.
Whether the prognosis of ILD in patients with polymyositis is different from that in patients with dermatomyositis is uncertain. In a recent study by Fujisawa et al. [38 • ], patients with dermatomyositis and associated ILD were less responsive to corticosteroid therapy compared with patients with polymyositis-associated ILD, resulting in a poor prognosis. An aggressive course of ILD, often with a fatal outcome, was also reported in a few patients with amyopathic dermatomyositis, a variant of dermatomyositis that is characterized by the typical skin rash but without myositis [20 • , 21, 22] . Digital infarcts with microangiopathy in patients with dermatomyositis were also suggestive of severe pulmonary involvement and poor prognosis [39 • ].
Treatment
The optimal treatment for myositis-associated ILD is not known. No published controlled trials exist on the effects of different therapies in polymyositis/dermatomyositis with associated ILD. Thus, available information on treatment efficacy is based on small case series or case reports. Corticosteroid therapy is often used as a first-line treatment, as in the case of patients with myositis without ILD. Initial therapy usually recommended is prednisolone with a dosage of 0.75-1 mg/kg/day for 6-8 weeks and subsequent tapering depending on clinical and laboratory evaluation. Corticosteroid treatment as a single agent is often not sufficient to cause improvement of ILD. Furthermore, the high doses required over a long period are often associated with severe side effects. Thus, other immunosuppressive agents are often required. The most frequently used drugs with reported beneficial effects on lung function are cyclophosphamide, cyclosporine A, azathioprine, and methotrexate [3,19,20 • ,40-42] . Pulse methylprednisolone in combination with intravenous cyclophosphamide has also been reported to be beneficial in patients with rapidly progressive ILD [19, 43] . Why only a limited number of patients respond to these therapies is unknown, but according to some reports, it could be related to different histopathology of ILD, suggesting different disease mechanisms. Furthermore, the response rate may be higher when treatment is initiated early in the course of the disease, before irreversible changes have developed.
One interesting case series suggested a beneficial effect of tacrolimus in polymyositis-associated ILD [44] . In this preliminary study, tacrolimus led to stabilization or improvement of ILD in four of five anti-Jo1 antibodypositive patients with polymyositis. These observations were confirmed in a larger patient cohort of 13 patients with myositis and anti-aminoacyl-tRNA synthetase antibodies-associated ILD, in which significant improvement was observed in all pulmonary parameters, including FVC, FEV 1 , and DLco after an average treatment for 51.2 (range, 6-120) months [45] .
Tumor necrosis factor a (TNF-a) inhibitors have become promising agents for treatment of many rheumatic diseases. Whether TNF-a inhibitors are effective in patients with myositis with ILD is not known. Notably, there have been a few case reports in which ILD developed in patients with rheumatoid arthritis during treatment with TNF-a inhibitors [46 • ].
Whether these immune-modulating agents really have an effect in myositis-associated ILD requires confirmation by prospective, randomized controlled trials. For patients who develop severe end-stage ILD, refractory to medical therapy, lung transplantation could be considered as a possible therapy, but there are no published reports to date on the outcome of lung transplants in patients with myositis and ILD.
Careful follow-up of lung function and HRCTof the lungs is important to assess course and treatment response in individual patients who have signs of ILD. In idiopathic pulmonary fibrosis, if response occurs, improvement of lung function and regression of changes on the radiograph/HRCT is usually noted within 3 months. Thus, in patients with myositis with ILD, follow-up assessment including pulmonary function tests and radiograph and/or HRCT after approximately 3 months of therapy is recommended to evaluate treatment response. It is not known how long immunosuppressive treatment is required, but the beneficial effects need to be balanced with the risk of serious side effects inevitably associated with long-term immunosuppressive therapy. When cyclophosphamide is used as induction therapy, replacement with a less toxic immunosuppressive agent such as azathioprine, methotrexate, or cyclosporine A should be considered later during the treatment, but when the replacement could be made is uncertain and should be based on clinical assessment in combination with evaluation of pulmonary function tests and HRCT of the lungs.
Conclusion
Investigations to detect interstitial lung disease should be performed during the initial evaluation as well as during follow-up of patients with myositis, because ILD is a frequent manifestation in patients with polymyositis or dermatomyositis and because ILD is associated with increased morbidity and mortality. This evaluation should include chest radiograph, HRCT of lungs, pulmonary function tests including diffusing capacity, and serum levels of anti-Jo1 antibodies. In the patients with ILD, clinical or subclinical, treatment with high doses of corticosteroids in combination with other immunosuppressive therapy should be initiated. Some histopathologic features including DAD, UIP, neutrophil alveolitis, digital infarcts showing microangiopathy in dermatomyositis, and amyopathic dermatomyositis have all been reported as risk factors for poor outcome. Presence of these factors suggests the use of aggressive immunosuppressive therapy and careful monitoring of lung function.
